Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
Omeros (OMER): Breaking Down the $27.50 Price Target and +65% Upside Potential

Omeros (OMER): Breaking Down the $27.50 Price Target and +65% Upside Potential

Key Takeaways

  • The central $27.50 price target is the arithmetic mean of the two most current, attributable analyst targets: $22 (Cantor Fitzgerald) and $33 (H.C. Wainwright), a range of $22 to $33.
  • With OMER last closing near $16.68, reaching $27.50 implies upside of roughly 65%, a very large required move.
  • Analyst coverage is thin — only a handful of active targets — so the average is sensitive to any single revision, and some aggregators show higher figures because they still include dated, high targets.
  • The strongest support comes from the commercial launch of YARTEMLEA, Omeros's lead drug, which posted sharply higher quarterly revenue.
  • The biggest near-term risk is a negative European regulatory opinion on narsoplimab, plus ongoing GAAP losses and shareholder dilution.
  • For more on this ticker's Major News, Today's Price Move, Forecast, and Earnings, visit the dedicated pages.
  • Explore Trending AI Robots to see AI-driven trading strategies applied across the market.

Understanding the Analyst Targets

Omeros Corporation (OMER), a Seattle-based commercial-stage biopharmaceutical company, has a thin sell-side coverage base. The two most current, individually verifiable analyst price targets are a $33 target from H.C. Wainwright's Brandon Folkes (Buy, October 16, 2026, lowered from $40 following a negative European CHMP opinion) and a $22 target from Cantor Fitzgerald's Olivia Brayer Saunders (Overweight, October 14, 2026, following an upgrade on a better-than-expected YARTEMLEA launch). Averaging those two gives the central $27.50 figure used here.

The $11 gap between the high and low reflects genuine disagreement about how durable YARTEMLEA's launch momentum will prove and how much the European regulatory setback on narsoplimab matters. Older targets — such as WBB Securities' $55 (May 2026) and D. Boral Capital's $36 (December 2025) — are stale and were excluded, which is why some third-party screens still show a higher average. The mean should be read as a reference point, not a guaranteed outcome. I also checked this using Tickeron’s AI Daily Buy/Sell Signals to get a sense of how the stock has been reacting to recent news flow.

Current Market Position and Path Toward the Target

At its most recent close, OMER traded near $16.68, within a 52-week range of $6.70 to $21.24. Reaching $27.50 would require a rise of about 65%, a very large move that would also take the stock well above its prior 52-week high. The path hinges primarily on continued growth in YARTEMLEA (narsoplimab-wuug), Omeros's FDA-approved therapy for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA). Gross revenue for YARTEMLEA reached $41.8 million in the third quarter of 2026, up 29.6% sequentially, and Omeros generated positive operating cash flow of $13.3 million while holding $95.3 million in cash and short-term investments. Whether the shares can sustain a re-rating depends on converting early launch momentum into durable, profitable growth.

Factors That Could Support a Move Toward the Target

  • Launch momentum: YARTEMLEA revenue has grown sequentially and beat consensus expectations, driving the Cantor Fitzgerald upgrade.
  • Improving profitability metrics: Non-GAAP adjusted net income turned positive in recent quarters, and the company is generating positive operating cash flow.
  • Balance-sheet actions: Omeros repurchased $30.5 million of its 2029 convertible notes and has been buying back shares, reducing potential future dilution.
  • Broader pipeline: Programs such as OMS1029 (long-acting MASP-2 inhibitor) and OMS527 (PDE7 inhibitor) offer optionality beyond a single product.
  • Upward estimate revisions: Omeros has logged positive earnings-per-share (EPS) revisions with no negative revisions over the trailing 90 days.

Risks That Could Prevent Reaching the Target

  • European regulatory setback: The EMA's CHMP issued a negative opinion on the marketing authorization application for narsoplimab in TA-TMA, prompting H.C. Wainwright to cut its target.
  • GAAP losses: The third quarter included a $62.0 million non-cash, mark-to-market derivative loss tied to the 2029 notes, producing a GAAP net loss despite adjusted profitability.
  • Dilution: Shares outstanding rose roughly 36% year over year, a recurring feature of small-cap biotech financing.
  • Concentration risk: The investment thesis depends heavily on one commercial product in a niche indication.
  • Volatility: With a beta near 3, the stock can swing sharply on news, and shares fell further in after-hours trading following the latest results.

Technical Levels and Market Structure

The stock's 52-week high near $21.24 (September 2026) acts as the first major resistance zone; a decisive close above it would be required before any move toward $27.50 becomes technically plausible. On the downside, the recent low near $16.64 provides near-term support, with the 200-day moving average near $13.77 and the 50-day average near $18.27 marking intermediate reference points. The round $20 level is also a psychological barrier. The shares trade below their 50-day average after a pullback from the September high.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a research horizon of about 12 months, though the precise horizon is rarely stated and varies by firm. Investors should watch YARTEMLEA prescription and revenue trends each quarter, any progress or appeal on the European regulatory front, FDA interactions, cash burn and cash balances, updates on the remaining 2029 notes, and any further analyst target revisions. Pipeline readouts for OMS1029 and OMS527 are also relevant longer-term catalysts.

Using AI Tools for Deeper Insights

In my own research process, I find AI Daily Buy/Sell Signals helpful for monitoring volatile names like this one. The tool applies artificial intelligence to track thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on market conditions and technical behavior. It offers a data-driven layer that complements fundamental analysis, especially when coverage is thin and news can move the stock quickly.

Final Assessment

The $27.50 target for Omeros Corporation (OMER) is the average of the two most current analyst targets ($22 to $33), not an official consensus, and it implies a very large advance of roughly 65% from a recent price near $16.68. The bull case rests on YARTEMLEA's accelerating commercial launch and improving cash generation; the bear case centers on the negative European CHMP opinion, recurring GAAP losses, dilution, and the stock's extreme volatility. With such thin coverage and a wide target range, the figure is best treated as a directional benchmark rather than a forecast. Monitor quarterly launch data, regulatory developments, and any analyst revisions for the next meaningful signal.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: OMER

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


OMER's RSI Oscillator ascending out of oversold territory

The RSI Oscillator for OMER moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In 28 of the 29 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +8.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where OMER advanced for three days, in 217 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

OMER may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 58 cases where OMER's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.

The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OMER as a result. In 69 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.

The Moving Average Convergence Divergence Histogram (MACD) for OMER turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 37 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.

OMER moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for OMER crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where OMER declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

The Aroon Indicator for OMER entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-23.853) is normal, around the industry mean (3.586). P/E Ratio (8.812) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (35.714) is also within normal values, averaging (440.869).

The Tickeron SMR rating for this company is 11 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. OMER’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 37 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -10%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was -22%. PEPG experienced the highest price growth at 75%, while ALGS experienced the biggest fall at -58%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -24%. For the same stocks of the Industry, the average monthly volume growth was 6% and the average quarterly volume growth was -35%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 43
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of pharmaceutical products

Industry Biotechnology

Industry
Biotechnology
Address
201 Elliott Avenue West
Phone
+1 206 676-5000
Employees
175
Web
https://www.omeros.com
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
SKHY fell -6.87% to $122.74 by 10:04 a.m. ET, down $9.05 from Friday's close of $131.79, extending a premarket decline into the regular session. The drop was driven by a sector-wide AI chip selloff ahead of Nvidia's quarterly results on Tuesday, where CEO Jensen Huang's resignation has raised doubts about the durability of data-center spending that underpins high-bandwidth memory demand.